{"id":"NCT00901901","sponsor":"Bayer","briefTitle":"Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma","officialTitle":"A Phase III Randomized, Placebo Controlled, Double Blind Trial of Sorafenib Plus Erlotinib vs. Sorafenib Plus Placebo as First Line Systemic Treatment for Hepatocellular Carcinoma (HCC)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-05-21","primaryCompletion":"2012-04-17","completion":"2018-05-23","firstPosted":"2009-05-14","resultsPosted":"2013-09-30","lastUpdate":"2019-05-30"},"enrollment":732,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Carcinoma, Hepatocellular"],"interventions":[{"type":"DRUG","name":"Sorafenib (Nexavar, BAY43-9006)","otherNames":[]},{"type":"DRUG","name":"Erlotinib (Tarceva)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Sorafenib (Nexavar, BAY43-9006) + Erlotinib (Tarceva)","type":"EXPERIMENTAL"},{"label":"Sorafenib (Nexavar, BAY43-9006) + Placebo","type":"ACTIVE_COMPARATOR"}],"summary":"This is a randomized trial to evaluate the clinical benefit of sorafenib 400 mg twice daily and erlotinib 150 mg once a day versus sorafenib 400 mg twice daily and placebo erlotinib once daily in subjects with unresectable advanced or metastatic Child-Pugh A HCC. Patients who are candidates for potentially curative intervention (i.e. surgical resection or local ablation) are not eligible for this study.","primaryOutcome":{"measure":"Overall Survival","timeFrame":"From randomization of the first patient until 34 months or date of death of any cause whichever came first","effectByArm":[{"arm":"Sorafenib (Nexavar, BAY43-9006) + Erlotinib (Tarceva)","deltaMin":289,"sd":null},{"arm":"Sorafenib (Nexavar, BAY43-9006) + Placebo","deltaMin":259,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":7},"locations":{"siteCount":127,"countries":["United States","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","Chile","China","Colombia","France","Germany","Greece","Hong Kong","Israel","Italy","New Zealand","Peru","Poland","Russia","Singapore","South Africa","South Korea","Spain","Taiwan","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["http://www.clinicaltrialsregister.eu/"]},"adverseEventsSummary":{"seriousAny":{"events":214,"n":362},"commonTop":["Diarrhea","Diarrhea","Fatigue","Fatigue","Rash/desquamation"]}}